UK drugs watchdog approves new Covid treatment Xevudy

Drug found in trials to cut vulnerable adults' risk of hospital admission and death by 79%

• Coronavirus - latest updates
• See all our coronavirus coverage

The UK drugs watchdog has approved a new Covid treatment after trials found it cut the likelihood of hospital admission and death by 79% in high-risk adults.

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Xevudy (sotrovimab), a monoclonal antibody made by GlaxoSmithKline (GSK) and Vir Biotechnology, for people with mild to moderate Covid-19 at high risk of developing severe disease.